中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
10期
1449-1450
,共2页
咳嗽变异性哮喘%氨溴特罗%孟鲁司特钠%疗效
咳嗽變異性哮喘%氨溴特囉%孟魯司特鈉%療效
해수변이성효천%안추특라%맹로사특납%료효
Cough variant asthma%Ambroxol and clenbuterol%Montelukast sodium%Effect
目的 观察氨溴特罗口服联合孟鲁司特钠佐治咳嗽变异性哮喘的疗效.方法 将74例咳嗽变异性哮喘患儿完全随机分为2组,对照组(36例)给予孟鲁司特钠口服；观察组(38例)在对照组的基础上加用氨溴特罗口服液治疗.对2组的咳嗽缓解时间和消失时间以及治疗前后肺功能指标变化和晨、晚间最大呼气流量(PEF)值变化等情况进行比较.结果 观察组咳嗽缓解时间和咳嗽消失时间分别为(5.6±1.7)和(7.8±2.3)d,明显短于对照组的(7.8±2.3)和(12.2±2.0)d,差异均有统计学意义(均P＜0.05).治疗后对照组和观察组第1秒用力呼气容积、第1秒用力呼气容积/用力肺活量、最大呼气流量明显改善[观察组:(89±9)L比(75±10)L,(84±5)％比(74±15)％,(90±9) L/s比(85±12)L/s；对照组:(82±11)L比(77±13)L,(81±5)％比(76±10)％,(87±4) L/s比(84±15)L/s；均P＜0.05],观察组患儿治疗后肺功能指标明显优于对照组患儿(均P＜0.05).结论 氨溴特罗口服液联合孟鲁司特钠治疗咳嗽变异性哮喘疗效可靠.
目的 觀察氨溴特囉口服聯閤孟魯司特鈉佐治咳嗽變異性哮喘的療效.方法 將74例咳嗽變異性哮喘患兒完全隨機分為2組,對照組(36例)給予孟魯司特鈉口服；觀察組(38例)在對照組的基礎上加用氨溴特囉口服液治療.對2組的咳嗽緩解時間和消失時間以及治療前後肺功能指標變化和晨、晚間最大呼氣流量(PEF)值變化等情況進行比較.結果 觀察組咳嗽緩解時間和咳嗽消失時間分彆為(5.6±1.7)和(7.8±2.3)d,明顯短于對照組的(7.8±2.3)和(12.2±2.0)d,差異均有統計學意義(均P＜0.05).治療後對照組和觀察組第1秒用力呼氣容積、第1秒用力呼氣容積/用力肺活量、最大呼氣流量明顯改善[觀察組:(89±9)L比(75±10)L,(84±5)％比(74±15)％,(90±9) L/s比(85±12)L/s；對照組:(82±11)L比(77±13)L,(81±5)％比(76±10)％,(87±4) L/s比(84±15)L/s；均P＜0.05],觀察組患兒治療後肺功能指標明顯優于對照組患兒(均P＜0.05).結論 氨溴特囉口服液聯閤孟魯司特鈉治療咳嗽變異性哮喘療效可靠.
목적 관찰안추특라구복연합맹로사특납좌치해수변이성효천적료효.방법 장74례해수변이성효천환인완전수궤분위2조,대조조(36례)급여맹로사특납구복；관찰조(38례)재대조조적기출상가용안추특라구복액치료.대2조적해수완해시간화소실시간이급치료전후폐공능지표변화화신、만간최대호기류량(PEF)치변화등정황진행비교.결과 관찰조해수완해시간화해수소실시간분별위(5.6±1.7)화(7.8±2.3)d,명현단우대조조적(7.8±2.3)화(12.2±2.0)d,차이균유통계학의의(균P＜0.05).치료후대조조화관찰조제1초용력호기용적、제1초용력호기용적/용력폐활량、최대호기류량명현개선[관찰조:(89±9)L비(75±10)L,(84±5)％비(74±15)％,(90±9) L/s비(85±12)L/s；대조조:(82±11)L비(77±13)L,(81±5)％비(76±10)％,(87±4) L/s비(84±15)L/s；균P＜0.05],관찰조환인치료후폐공능지표명현우우대조조환인(균P＜0.05).결론 안추특라구복액연합맹로사특납치료해수변이성효천료효가고.
Objective To observe the effect of ambroxol and clenbuterol and montelukast sodium in cough variant asthma(CVA).Methods A total of 74 children with CVA were enrolled.All the patients were divided into control group and observation group randomly.Children in control group were given montelukast sodium,in observation group were given montelukast sodium plus ambroxol and clenbuterol.The clinical symptoms,pulmonary function and peak expiratory flow were compared between the two groups.Results There was a significant difference between observation group and control group in remission time of cough and cough disappearance time[(5.6 ± 1.7)d vs (7.8 ± 2.3) d,(7.8 ± 2.3) d vs (12.2 ± 2.0) d,P ＜ 0.05].Compared to before treatment,patients in observation group had improved in pulmonary function after treatment [obsenation group:(89 + 9) L vs (7.5 ± 10) L,(84 ±5)％vs(74 ± 15)％,(90 ±9)L/s vs (85 ± 12)L/s; control group:(82 ± 11)L vs (77 ± 13)L,(81 ±5)％ vs (76 ± 1 0) ％,(87 ± 4) L/s vs (84 ± 15) L/s ; all P ＜ 0.05].Conclusion A combination treatment including ambroxol and clenbuterol and montelukast sodium is effective for children with CVA.
